Minimal Residual Disease (MRD) Testing Market Size to Surge USD 4.72 Billion by 2034

Market Key Takeaways

• North America dominated the minimal residual disease (MRD) testing market with around 45% share in 2024.
• Asia Pacific is expected to witness the fastest growth from 2025 to 2034.
• By technology, the flow cytometry (FC) segment held the largest market share of about 40% in 2024.
• By technology, the next-generation sequencing (NGS) segment is expected to grow at the fastest CAGR from 2025 to 2034.
• By application, the hematological malignancies segment dominated the market with around 65% share in 2024.
• By application, the solid tumors segment is expected to grow at a significant CAGR from 2025 to 2034.
• By end-user, the hospitals & specialty clinics segment led the market with around 50% share in 2024.
• By end-user, the diagnostic laboratories segment is expected to grow at the fastest CAGR from 2025 to 2034.

Market Overview

Minimal Residual Disease (MRD) testing is a highly sensitive diagnostic approach used to detect trace amounts of cancer cells that persist in a patient’s body after treatment—levels often too low to be identified by conventional diagnostic methods. These residual malignant cells pose a significant risk of disease relapse, making MRD testing an essential component in the management of hematologic malignancies, including leukemia, lymphoma, and multiple myeloma.

MRD testing leverages advanced technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry to identify and quantify minimal disease levels with remarkable precision. By providing clinicians with early insight into treatment effectiveness, MRD testing enables personalized therapy adjustments, timely interventions, and improved long-term patient outcomes. As oncology care shifts toward precision medicine, MRD testing is becoming a critical tool in disease monitoring, guiding treatment decisions, and improving relapse prediction across both clinical and research settings.

AI Impact on the Minimal Residual Disease Testing Market

Artificial Intelligence (AI) is revolutionizing the Minimal Residual Disease (MRD) testing market by enhancing diagnostic precision, speed, and reproducibility across complex cancer detection workflows. In high-dimensional techniques such as flow cytometry, AI algorithms can analyze cellular data in seconds rather than minutes, dramatically reducing manual workload and human error. This acceleration not only streamlines laboratory operations but also improves diagnostic turnaround times—crucial for timely treatment adjustments and relapse prevention.

AI’s ability to process and interpret multi-parametric datasets enables more accurate identification of rare cell populations, improving the sensitivity and reliability of MRD detection even in heterogeneous cancer profiles. By integrating machine learning (ML) and deep learning models, laboratories can uncover subtle patterns and develop novel biomarkers that enhance disease monitoring and patient stratification. Furthermore, AI-driven automation democratizes access to advanced MRD testing, allowing smaller laboratories and healthcare systems to implement sophisticated analyses without requiring extensive expert oversight. Ultimately, AI is paving the way toward data-driven oncology, where real-time insights, predictive analytics, and standardized diagnostics redefine how minimal residual disease is detected, monitored, and managed.

Market Opportunities

The Minimal Residual Disease (MRD) testing market presents significant growth opportunities as precision oncology and personalized medicine continue to advance. One of the primary opportunities lies in the expanding clinical adoption of MRD testing across solid tumors, beyond its traditional use in hematologic malignancies such as leukemia and multiple myeloma. As evidence grows supporting MRD’s role as a surrogate endpoint in clinical trials, pharmaceutical companies are increasingly integrating MRD testing into drug development pipelines to assess treatment efficacy and accelerate regulatory approvals.

The rising demand for next-generation sequencing (NGS)-based MRD assays offers opportunities for diagnostic companies to innovate in assay design, automation, and bioinformatics. Additionally, the integration of AI and cloud-based analytics can enhance data interpretation and reporting accuracy, opening avenues for scalable, standardized MRD testing across decentralized labs. Partnerships between diagnostic developers, biotech firms, and academic research institutions are expanding the use of MRD testing in clinical decision-making, companion diagnostics, and longitudinal disease monitoring. Emerging markets also present growth potential as healthcare infrastructure improves, creating new opportunities for affordable, high-sensitivity MRD solutions in oncology care.

Regional Insights

The North American region dominates the global MRD testing market, driven by the high incidence of hematologic cancers, robust healthcare infrastructure, and strong presence of leading diagnostic companies. The United States leads in MRD testing adoption, supported by early integration of NGS and AI-based platforms, favorable regulatory frameworks, and reimbursement coverage for precision diagnostics. Major collaborations between pharmaceutical firms and diagnostic laboratories are further expanding MRD applications in oncology clinical trials.

Europe represents the second-largest market, with countries such as the U.K., Germany, and France advancing in the use of MRD testing within both clinical practice and research settings. Supportive healthcare policies, growing investments in precision oncology, and widespread clinical validation of MRD assays are key regional growth drivers. The European Medicines Agency (EMA)’s recognition of MRD as a potential clinical endpoint is also accelerating its adoption across hematologic and solid tumor studies.

The Asia-Pacific region is expected to witness the fastest market growth, fueled by a rising cancer burden, expanding healthcare access, and increased government focus on early diagnosis and personalized treatment. Countries such as China, Japan, South Korea, and India are rapidly investing in genomic infrastructure and molecular diagnostic capabilities, paving the way for broader MRD testing implementation. Local partnerships and technology transfers from global players are also strengthening regional capabilities.

Recent Developments

• In June 2025, Tracer Biotechnologies partnered with QIAGEN to develop MRD assays for solid tumors on the QIAcuity dPCR platform, aiming for sensitive and cost-effective testing. Tracer offers two solutions: a tumor-informed dPCR assay and an AI-powered ctDNA platform for ultra-sensitive detection.
• In March 2025, Veracyte revealed the presentation of multiple abstracts at the EAU25 congress, showcasing the performance of its Decipher tests in prostate and bladder cancer, along with new data on its MRD testing for muscle-invasive bladder cancer from the TOMBOLA trial.
• In January 2025, Adaptive Biotechnologies and NeoGenomics announced a collaboration to enhance MRD monitoring for blood cancers with Adaptive’s clonoSEQ®, the only FDA-cleared test for MRD detection in lymphoid cancers, integrated with NeoGenomics’ COMPASS® and CHART®. This partnership aims to provide personalized treatment strategies for patients by offering real-time insights into disease progression.
• In January 2025, Datar Cancer Genetics (DCG) launched Target-MRD, an advanced blood test for solid organ cancers that uses NGS and personalized droplet digital PCR (dd-PCR) to monitor MRD. This test aims to detect a small number of tumor cells that can lead to relapse by combining tumor-agnostic and tumor-informed biomarkers for effective disease management.

Get Sample Link: https://www.precedenceresearch.com/sample/7039